Ivie v. AstraZeneca Pharmaceuticals, LP

CourtDistrict Court, D. Oregon
DecidedOctober 23, 2024
Docket3:19-cv-01657
StatusUnknown

This text of Ivie v. AstraZeneca Pharmaceuticals, LP (Ivie v. AstraZeneca Pharmaceuticals, LP) is published on Counsel Stack Legal Research, covering District Court, D. Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ivie v. AstraZeneca Pharmaceuticals, LP, (D. Or. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF OREGON

SUZANNE IVIE, Case No. 3:19-cv-01657-JR

Plaintiff, OPINION AND ORDER

v.

ASTRAZENECA PHARMACEUTICALS, LP,

Defendant. ____________________________ RUSSO, Magistrate Judge: Plaintiff Suzanne Ivie commenced this action against defendant AstraZeneca Pharmaceuticals in October 2019 for alleged violations of state and federal employment law. All parties have consented to allow a Magistrate Judge enter final orders and judgment in this case in accordance with Fed. R. Civ. P. 73 and 28 U.S.C. § 636(c). Defendant now moves for a new trial pursuant to Fed. R. Civ. P. 59. For the reasons stated below, defendant’s motion is granted. BACKGROUND The history of this matter is well known to the parties, such that it will only be repeated to the extent necessary to provide context for the present motion. Plaintiff, a Utah resident, initiated this action in Oregon, alleging venue in Oregon was

proper because “a substantial portion of the unlawful employment practices occurred within this judicial district.” First Am. Compl. ¶ 4 (doc. 35). Namely, defendant “is a Delaware corporation and conducts significant business in Oregon,” and plaintiff “oversaw approximately eight Sales Representatives who worked on accounts in Utah, Idaho, and parts of Oregon” in her role as Executive District Sales Manager with defendant. Id. at ¶¶ 6, 13. Following the Court’s March 2021 summary judgment ruling (largely denying defendant’s motion), the following claims remained for trial: (1) discrimination/retaliation under the Age Discrimination in Employment Act (“ADEA”); (2) discrimination under Or. Rev. Stat. § 659A.030; (3) retaliation under the False Claims Act (“FCA”); (4) retaliation under Or. Rev. Stat. § 659A.199; (5) discrimination/retaliation under the federal Family and Medical Leave Act; and

(6) discrimination/retaliation under the Oregon Family Leave Act. See generally Ivie v. AstraZeneca Pharms., LP, 2021 WL 1198306 (D. Or. Mar. 28, 2021). In the parties’ joint pretrial order, defendant provided general denials in regard to each of plaintiff’s state law claims but did not raise any specific issues concerning venue. Joint Pretrial Order 19-20 (doc. 66). In June 2021, a six-day jury trial was held. At the close of plaintiff’s case-in-chief, defendant moved for judgment as a matter of law (“JMOL”) under Fed. R. Civ. P. 50(a) on the state law claims, arguing there was insufficient evidence adduced at trial to allow those claims to go forward. That is, defendant asserted that Oregon’s statutes could not be applied extraterritorially to benefit a non-resident, when no wrongful conduct took place in Oregon. Trial Tr. Vol. 5, 848, 968-72 (doc. 170). Defendant filed a written motion contemporaneously. The case was then submitted to the jury, who ruled in favor of plaintiff solely in regard to her whistleblower retaliation claim under Or. Rev. Stat. § 659A.199, awarding $510,423 in economic damages and $1,872,000

in non-economic damages. Defendant thereafter renewed its JMOL motion under Fed. R. Civ. P. 50(b) and, alternatively, sought a new trial pursuant to Fed. R. Civ. P. 59. The Court granted defendant’s Rule 50(b) motion, vacated the jury verdict, and entered judgment in favor of defendant. See generally Ivie v. AstraZeneca Pharms., LP, 2021 WL 5167283 (D. Or. Nov. 5, 2021), rev’d & remanded, 2023 WL 3563007 (9th Cir. May 19, 2023), cert. denied, 144 S. Ct. 495 (2023). Specifically, the Court rejected plaintiff’s arguments surrounding waiver and otherwise found she “failed to present facts required for the jury to find [in her favor] on the whistleblower protection claim,” and that “uphold[ing] the jury’s verdict would violate Oregon’s state law presumption against extraterritoriality [and] choice of law rules [as well as] the Fourteenth Amendment.” Ivie, 2021

WL 5167283 at *1-5. On appeal, the Ninth Circuit reversed and remanded as follows: This case presents a straightforward matter of civil procedure. Ivie asserts that AstraZeneca forfeited or waived its “Oregon-nexus argument” by failing to raise it in the parties’ joint pretrial order or at any time prior to its initial JMOL motion brought at the close of Ivie’s case . . . We agree with Ivie [and] have repeatedly emphasized that a party may not offer evidence or advance theories at the trial which are not included in the pretrial order or which contradict its terms. This requirement extends to any and all theories, which means that a defendant must enumerate its defenses in a pretrial order even if the plaintiff has the burden of proof.

AstraZeneca’s frank admission that it failed to include the negative “Oregon-nexus” defense in the pretrial order resolves whether its Rule 50(b) motion raised a theory outside of the scope of that order . . . Falling back, AstraZeneca’s last-ditch defense of the judgment below is to assert the plain error doctrine, the district court’s alternative ground for its decision. Plain error is a rare species in civil litigation, encompassing only those errors that reach the pinnacle of fault. Among other requirements, plain error review applies only when needed to prevent a miscarriage of justice, meaning that the error seriously impaired the fairness, integrity, or public reputation of judicial proceedings.

[But] AstraZeneca does not attempt to show that merely applying the wrong state’s law seriously impaired the fairness, integrity, or public reputation of judicial proceedings. Choice-of-law errors are (regrettably) a routine occurrence in civil litigation, and we will be very busy indeed on plain error review if we get into the business of overturning jury verdicts based on such errors.

We reverse the district court’s order granting AstraZeneca’s renewed motion for judgment as a matter of law, and we remand with instructions for the court to consider in the first instance whether the company’s motion for new trial should be granted on the ground that the damages award was excessive.

Ivie, 2023 WL 3563007 at *1-3 (citations and internal quotations, brackets, and ellipses omitted). The Ninth Circuit expressly declined to resolve whether “AstraZeneca’s failure [to raise its Oregon-nexus argument in the joint pretrial order] was a forfeiture or a waiver.” Id. at *1 n.1. Likewise, the Ninth Circuit did not reach the merits of defendant’s Oregon-nexus defense; the only comment on the substantive aspects of the Court’s decision came from the dissent: Based on AstraZeneca’s pleadings, the district court concluded that Ivie had “adequate notice” of the defense—presumably meaning that Ivie would not be prejudiced by AstraZeneca’s raising of the defense in the Rule 50(b) motion. That doesn’t seem wrong—Ivie hasn’t proffered any additional evidence that she would have admitted at trial if she had more express notice of the extraterritorial defense.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Allied Chemical Corp. v. Daiflon, Inc.
449 U.S. 33 (Supreme Court, 1980)
Memphis Community School District v. Stachura
477 U.S. 299 (Supreme Court, 1986)
United States v. Olano
507 U.S. 725 (Supreme Court, 1993)
McKennon v. Nashville Banner Publishing Co.
513 U.S. 352 (Supreme Court, 1995)
Molski v. M.J. Cable, Inc.
481 F.3d 724 (Ninth Circuit, 2007)
Sloane v. Equifax Information Services, LLC
510 F.3d 495 (Fourth Circuit, 2007)
Crown Central Petroleum Corp. v. Brice
427 F. Supp. 638 (E.D. Virginia, 1977)
Ackerman v. Western Elec. Co., Inc.
643 F. Supp. 836 (N.D. California, 1986)
Bush v. Texaco, Inc.
504 F. Supp. 670 (E.D. Texas, 1981)
Steel Co. v. Citizens for a Better Environment
523 U.S. 83 (Supreme Court, 1998)
Justice v. Rockwell Collins, Inc.
117 F. Supp. 3d 1119 (D. Oregon, 2015)
Alice Huff v. Pete Buttigieg
42 F.4th 638 (Seventh Circuit, 2022)
Fresquez v. BNSF Railway
52 F.4th 1280 (Tenth Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
Ivie v. AstraZeneca Pharmaceuticals, LP, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ivie-v-astrazeneca-pharmaceuticals-lp-ord-2024.